Prasugrel clinical trials
Also written Effient, Efient, LY640315 and CS-747.
How each study uses prasugrel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prasugrel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Jul 2009 · EFFIENT · NDA 022307 (FDA, Drugs@FDA)
- European Union
- 24 Feb 2009 · Efient · EMEA/H/C/000984 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
113 studies that test it; most in 2011 (16)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 15 |
| 2011 | 16 |
| 2012 | 14 |
| 2013 | 12 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 86
Eli Lilly and Company (20) · University of Florida (8) · University of Patras (7) · Dong-A University (5) · Daiichi Sankyo (3) · Gennaro Sardella (3) · Seoul National University Hospital (2) · Gyeongsang National University Hospital (2)
Often tested with
Tested in the same studies.
Ticagrelor (31) · Clopidogrel (25) · Aspirin (3) · Bivalirudin (2) · Selatogrel (1) · Cilostazol (1) · Ritonavir (1) · Abciximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test prasugrel.
- Nov 2026Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) StudyPhase 4 · University of Florida
- Dec 2026Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsPhase 4 · University of Florida
- Aug 2027Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)Phase 4 · University of Florida
Studies
Open first, then newest update. How each study uses prasugrel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 113
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsRecruitingPhase 4University of FloridaNCT06691191Written as Prasugrel 10 mg
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)RecruitingPhase 4University of FloridaNCT07025148Written as Prasugrel
- Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 MonthsRecruitingPhase 4Instituto de Investigación Sanitaria de la Fundación Jiménez DíazNCT07507500Written as Prasugrel
- Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.RecruitingPhase 3Cardiocentro TicinoNCT07582835Written as Prasugrel
- Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) StudyRecruitingPhase 4University of FloridaNCT06821191Written as Prasugrel 5 mg
- Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)RecruitingPhase 4J.P.S HenriquesNCT06916520Written as Prasugrel 5 mg
- Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured AneurysmRecruitingPhase 4Yonsei UniversityNCT05359224Written as Prasugrel group
- Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary SyndromeCompletedPhase 4Vastra Gotaland RegionNCT05183178Written as Prasugrel 10 mg p.o
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)CompletedPhase 4Seoul National University HospitalNCT02193971Written as Prasugrel 5mg
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsCompletedPhase 1Viatris Innovation GmbHNCT03430661Written as Prasugrel
- The Elderly ACS II TrialCompletedPhase 4Azienda USL Reggio Emilia - IRCCSNCT01777503Written as prasugrel
- Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot StudyActive, not recruitingNot applicableMeditrix CorpNCT05117866Written as prasugrel Monotherapy
- Clopidogrel Monotherapy in Patients With High Bleeding RiskCompletedPhase 4Mayo ClinicNCT05223335Written as Prasugrel
- Platelet Inhibition in Patients With Systolic Heart FailureCompletedPhase 4University of NebraskaNCT01765400Written as Prasugrel 10 mg daily x 2 weeks
- Optical Coherence Tomography-Guided PCI With Single-Antiplatelet TherapyCompletedPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT04766437Written as Prasugrel 10mg
- Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised StudyCompletedPhase 4Germano Di SciascioNCT05643586Written as Prasugrel
- Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial AneurysmCompletedPhase 4Seoul National University HospitalNCT03581409Written as Prasugrel
- Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) StudyTerminatedPhase 4University of Maryland, BaltimoreNCT01452152Written as prasugrel
- Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or PrasugrelCompletedPhase 4University of Sao PauloNCT05247385Written as Prasugrel
- Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)CompletedPhase 4Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyNCT03672097Written as Prasugrel
See all 113 studies that test prasugrel →
Given beside what is tested · 10 — prasugrel is usual care or a partner of the new treatment
- Migraine Headaches Elimination With Patent Foramen Ovale-Directed TherapyRecruitingPhase 3Columbia UniversityNCT07629635Written as Prasugrel 5mg
- Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCICompletedPhase 4University of FloridaNCT04668144Written as Prasugrel
- Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and TicagrelorCompletedPhase 4University of FloridaNCT02545933Written as Prasugrel
- Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedPhase 3Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNCT02866175Written as Prasugrel
- Cangrelor to Clopidogrel or Prasugrel Transition StudyCompletedPhase 2The Medicines CompanyNCT01979445Written as Prasugrel
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary InterventionCompletedPhase 3Janssen Scientific Affairs, LLCNCT01830543Written as prasugrel
- Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)CompletedPhase 4Erasmus Medical CenterNCT02587260Written as Prasugrel
- Cangrelor Prasugrel Transition StudyCompletedPhase 2The Medicines CompanyNCT01852019Written as Prasugrel
- Study of Platelet Function After Administration of Aspirin Versus Lysine AcetylsalicylateCompletedPhase 1David VivasNCT02243137Written as prasugrel
- Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) PatientsCompletedPhase 2Eli Lilly and CompanyNCT01115738Written as Prasugrel
As the comparator · 14 — what is tested is compared with prasugrel
- Pharmacodynamic Evaluation of Switching From Prasugrel to TicagrelorCompletedNot applicableUniversity of FloridaNCT02016170Written as Prasugrel 10mg
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCompletedPhase 4University of FloridaNCT04006288Written as Prasugrel
- Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary SyndromeCompletedPhase 4Deutsches Herzzentrum MuenchenNCT01944800Written as Prasugrel
- A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:CompletedPhase 4University of FloridaNCT02065479Written as Prasugrel
- Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.CompletedPhase 4Insel Gruppe AG, University Hospital BernNCT02978040Written as Prasugrel
- Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes TrialCompletedPhase 4LMU KlinikumNCT01959451Written as Prasugrel
- Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by TicagrelorStatus unknownPhase 4Amsterdam UMC, location VUmcNCT02422888Written as Prasugrel
- Tailored Antiplatelet Therapy Versus Recommended Dose of PrasugrelCompletedPhase 4Assistance Publique - Hôpitaux de ParisNCT01538446Written as prasugrel / clopidogrel
- Ticagrelor and Endothelial FunctionStatus unknownPhase 4Hotel Dieu de France HospitalNCT02261922Written as prasugrel
- Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary InterventionCompletedPhase 4University of PatrasNCT01642966Written as Prasugrel
- Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic StudyCompletedPhase 4University of PatrasNCT01642940Written as Prasugrel
- Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary InterventionCompletedPhase 3University of PatrasNCT01360437Written as Prasugrel
- Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary InterventionCompletedPhase 3Assistance Publique Hopitaux De MarseilleNCT01505790Written as PRASUGREL
- Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)CompletedPhase 4University of PatrasNCT01463163Written as Prasugrel
Codes
What other systems call prasugrel · ClinicalTrials.gg INT006541
- MeSH (NLM) D000068799Prasugrel HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 34K66TBT99PRASUGRELConfirmed FDA, NLM, Wikidata
- RxNorm 613391Confirmed FDA, Wikidata
- Wikidata Q416232prasugrelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81566PrasugrelOne source FDA
- DrugBank DB06209One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068799 | Prasugrel Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 34K66TBT99 | PRASUGREL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 613391 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416232 | prasugrel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81566 | Prasugrel | One source FDA |
| DrugBank | DB06209 | — | One source Wikidata |
Also registered as prasugrel hydrochloride (UNII G89JQ59I13 · RxNorm 847020).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.